Product Description
Abetimus [Abetimus sodium, LJP 394, Rentol, Riquent] is a synthetic Toleragen molecule consisting of four double-stranded oligodeoxyribonucleotides attached to nonimmunogenic polyethylene glycol, a proprietary carrier platform. Abetimus is an immunomodulating agent that induces tolerance in B cells directed against double-stranded DNA (dsDNA). It does this by cross-linking surface antibodies. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12749759/)
Mechanisms of Action: Immunosuppressive
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innoviva
Company Location: Western America
Company CEO: Pavel Raifeld
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Lupus Nephritis|Kidney Diseases|Lupus Erythematosus, Systemic|Glomerulonephritis
Phase 2: Lupus Erythematosus, Systemic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00390091 |
LJP 394-90-16 | P2 |
Withdrawn |
Lupus Erythematosus, Systemic |
None |
2019-03-21 |
Treatments |
|
2008-004852-62 |
ABETIMUS FOR LUPUS NEPHRITIS | P3 |
Terminated |
Lupus Erythematosus, Systemic|Kidney Diseases |
2011-08-16 |
2022-03-12 |
Treatments |
|
NCT00089804 |
ASPEN | P3 |
Terminated |
Lupus Erythematosus, Systemic|Kidney Diseases|Lupus Nephritis |
2009-02-01 |
2019-03-21 |
||
2006-000674-73 |
2006-000674-73 | P3 |
Active, not recruiting |
Lupus Erythematosus, Systemic|Kidney Diseases |
2008-06-02 |
2022-03-12 |
Treatments |
|
NCT00035308 |
LJP 394-90-09 | P3 |
Completed |
Lupus Nephritis|Glomerulonephritis|Lupus Erythematosus, Systemic |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|